Tekla Ev To Sales from 2010 to 2025

HQH Stock  USD 16.72  0.09  0.54%   
Tekla Healthcare's EV To Sales is decreasing with slightly volatile movements from year to year. EV To Sales is predicted to flatten to 73.81. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
77.69195525
Current Value
73.81
Quarterly Volatility
194.28984673
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 188.3 K, Interest Expense of 0.0 or Selling General Administrative of 13.2 M, as well as many indicators such as Price To Sales Ratio of 73.81, Dividend Yield of 0.0222 or PTB Ratio of 1.0. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
  
Check out the analysis of Tekla Healthcare Correlation against competitors.

Latest Tekla Healthcare's Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Tekla Healthcare Investors over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Tekla Healthcare's EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Tekla Ev To Sales Regression Statistics

Arithmetic Mean254.48
Geometric Mean192.56
Coefficient Of Variation76.35
Mean Deviation169.84
Median168.30
Standard Deviation194.29
Sample Variance37,749
Range452
R-Value(0.89)
Mean Square Error8,318
R-Squared0.79
Slope(36.37)
Total Sum of Squares566,228

Tekla Ev To Sales History

2025 73.81
2024 77.69
2023 79.6
2022 104.06
2021 168.3
2020 117.03
2019 117.43

About Tekla Healthcare Financial Statements

Investors use fundamental indicators, such as Tekla Healthcare's Ev To Sales, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
EV To Sales 77.69  73.81 

Currently Active Assets on Macroaxis

When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:
Check out the analysis of Tekla Healthcare Correlation against competitors.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.145
Dividend Share
2.04
Earnings Share
3.53
Revenue Per Share
0.207
Quarterly Revenue Growth
0.172
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.